Continuous infusion of paclitaxel combined with cisplatin in the treatment of advanced non-small-cell lung cancer
- VernacularTitle:紫杉醇持续输注联合顺铂治疗晚期非小细胞肺癌
- Author:
Weiqing QU
;
Ping WANG
;
Enning ZHANG
- Publication Type:Journal Article
- Keywords:
non-small-cell lung cancer;
continuous infusion;
paclitaxel;
cisplatin
- From:
China Oncology
1998;0(04):-
- CountryChina
- Language:Chinese
-
Abstract:
Background and purpose:The incidence and mortality of lung cancer are markedly increasing all over the world, new drug and new methods in the treatment of lung cancer has been continuously explored and reported. Our study was to evaluate the efficacy and toxicity of continuous infusion of paclitaxel combined with cisplatin in the treatment of advanced non-small-cell lung cancer. Methods:61 patients were randomized into two groups, in the study group (31cases), the patients were treated with continuously infused paclitaxel for 48 hour at day1-2 with total dose 150 mg/m 2 , and cisplatin at day3,4,5 by intravenous injection with total dose 75 mg/m 2 . The patients in the control group(30 cases) received paclitaxel by intravenous injection for at least 3 hours at day 1, 8 with 150 mg/m 2 , and the same dose and administration of cisplatin as study group. More than three cycles were deliveried with three weeks apart to each cycle.Results:The objective response rates(RR) in the study group and control group were 54.84%(17/31)vs 43.33%(13/30),respectively; time to progress (TTP) were 7.1 months in the study group vs 5.8 months in the control group; median survival time (MST) were 14.0 months vs 10.2 months; 1-year survival rates were 67.74%(21/31)vs 33.33%(10/30)(P0.05). The toxicities that occurred in the two group included bone marrow suppression,nausea/vomiting, alopecia, peripheral neurotoxicity,impaired liver function,impaired renal function and phlebitis. There was no significant difference between the two groups in terms of the incidence of toxicites.Conclusions:In the treantment of advanced NSCLC , compared to conventional administration in delivery of the drugs, continuous infusion of paclitaxel can increase response rate and significantly improve 1-year survival fraction without the increase of toxicities.
